Unjha Formulations announces Smt. Krutiben M. Patel as new MD from May 2026. The company also scheduled its AGM for August 14, 2026, with a cut-off date of August 7, 2026, and proposed a ₹2 crore related party transaction.
Unjha Formulations Ltd Announces Leadership Change and AGM Details
Unjha Formulations Ltd has announced the appointment of Smt. Krutiben M. Patel as its new Managing Director, effective May 18, 2026. ## What just happened The company has appointed Smt. Krutiben M. Patel as Managing Director for three years starting May 18, 2026. Her starting salary will be ₹1,50,000 per month. The appointment follows the passing of the previous MD, Shri Mayank S. Patel. The company also proposed a related party transaction of ₹2 crore with Urvesh & Company for Psyllium Husk during FY2026-27. The 32nd Annual General Meeting (AGM) is scheduled for August 14, 2026, with a cut-off date for voting eligibility on August 7, 2026. Book closure is from August 8 to August 14, 2026. Smt. Jashodaben S. Patel is proposed for re-appointment as a director. ## Why this matters The leadership transition is significant for the company's future direction. The proposed related party transaction, valued at ₹2 crore, requires shareholder approval. The AGM details are crucial for shareholders to exercise their voting rights on these matters. ## The backstory Unjha Formulations Ltd is a listed entity on Indian stock exchanges. The company operates in the pharmaceutical sector, likely focusing on formulations and potentially herbal products given the mention of Psyllium Husk. The sudden demise of the former MD necessitates this leadership change. ## What changes now Smt. Krutiben M. Patel will now lead the company. Shareholders will vote on the proposed related party transaction and the re-appointment of Smt. Jashodaben S. Patel at the upcoming AGM. The company must ensure compliance with all regulatory requirements for these events. ## Risks to watch Any leadership transition can introduce uncertainty. The related party transaction needs careful scrutiny by shareholders to ensure it is fair and in the company's best interest. Compliance with Section 188 of the Companies Act, 2013, is critical. ## Peer comparison As an unlisted company, direct peer comparison is limited. However, in the pharmaceutical and herbal product sectors, transitions in key management roles and significant related party transactions are common occurrences that investors closely monitor for governance and operational stability. ## Context metrics (time-bound) * **New MD Effective Date:** May 18, 2026 * **AGM Date:** August 14, 2026 * **Cut-off Date for Voting:** August 07, 2026 * **Proposed RPT Value:** ₹2 crore (for FY2026-27) * **Director Re-appointment Record Date:** March 31, 2026 (shares held by Smt. Jashodaben S. Patel) ## What to track next Investors should track the outcome of the AGM regarding the related party transaction and director re-appointment. They should also monitor the company's performance under the new leadership post-May 2026.
